Skinvisible Pharmaceuticals, Inc.
Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, patent protected dermatology and healthcare products including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis along with sunscreens, anti-aging products,
alcohol-free hand sanitizing lotions, pre-surgical preparations, and various other medical treatments using its patented technology Invisicare®. Skinvisible's primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products. Click here to see current licensees.
The Technology: Invisicare® is a patented technology that enhances how drugs are delivered on, in or through the skin. It can control the release of active ingredients, providing a greater and longer release, while at the same time reducing irritation to the skin. It also binds products to the skin for 4 hours and more, resisting wash-off and rub-off. Skinvisible has developed a portfolio of 40+ topical products using Invisicare (prescription, over-the-counter and cosmeceutical) and also works directly with companies to enhance their products, especially ones coming off patent. Invisicare can be tailored to almost any type of molecule and the needs our customers. Learn more at www.invisicare.com.
Intellectual Property: Skinvisible's value lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. Patent approvals are sought in the U.S. and internationally for all products developed. Skinvisible has fourteen patents granted, including comprehensive patents on Invisicare, the foundation of all of our products; three in the US, and internationally in Canada, Europe (4), China, India, Australia, Hong Kong, and Korea. Additionally, Skinvisible has been granted three product specific patents in the US for dermal barrier products, sunscreens (photostability of avobenzone) and retinoids (stabilization). There are a number of U.S. and international (PCT) patents pending, with many more patent applications in progress. Some of these patents cover up to five products. All patents with Invisicare are owned by Skinvisible.
Click here to learn more about our patents.
The Opportunity: Pharmaceutical companies pursue new or improved revenue streams along with protecting their own patented products. New product formulations are expensive and time intensive for companies to undertake. Invisicare allows companies to sell a patent-protected product that has been revitalized with new benefits, providing a new story to help combat generic competitors. A perscription dermatology product can generate $100+ million per year; many even more - that's why a pharmaceutical company's investment into an Invisicare formulated product is a very viable option.
|
New Product Spotlight:
In the News:
Skinvisible featured in Drug Development & Delivery journal
Latest News:
SKINVISIBLE TRADES EXCLUSIVELY ON OTCQB
December 4, 2012
Skinvisible Granted US Patent for Topical Drug Delivery Technology
- Invisicare® Patent Protection Extends to Year 2029
November 27, 2012
Skinvisible Granted US Patent for Stabilizing Retinoids
- Intellectual Property Portfolio Strengthens
June 28, 2012
Skinvisible's Hand Sanitizer Kills "Super Bug" MRSA and E. coli For Up to 4 Hours
- Studies Confirm One Application of DermSafe As An Effective Long-Lasting Hand Sanitizer
April 12, 2012
Skinvisible Licensee Increases US Sales for Women's Health Product Made with Invisicare
- ProCort® Distribution Expands to Puerto Rico
March 7, 2012
Skinvisible Granted US Sunscreen Patent for UVA Absorber
- Broad Spectrum UVA / UVB Sunscreens with Invisicare Offer Eight Hours of Photostability
February 23, 2012
Skinvisible Formulation Submitted to European Union for Orphan Drug Designation
- Invisicare Formulation for Netherton Syndrome Under Review
CLICK HERE TO READ ALL NEWS RELEASES
Sign up for Skinvisible Inc. Updates:
Click here to join our mailing list.
|
Skinvisible Web
